No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S N/A · No P/S — trailing revenue unavailable or non-positive.
Annual revenue · last 7 fiscal years
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
The latest delayed quote for Baird Medical Investment Holdings Limited (BDMD) stock was $0.74 as of Oct 6, 2026, 9:55 AM EDT, down 0.39% from the previous close.
Longer view (total return, dividends reinvested): past 12 months -63.4% · 3-year avg -58.8%/yr
Based in China, Baird Medical Investment Holdings Limited and its associated entities specialize in engineering and commercializing microwave ablation medical apparatus. These sophisticated instruments are employed in the minimally invasive management of a diverse array of benign and malignant tumors, notably targeting thyroid nodules, hepatic carcinomas, pulmonary cancers, and mammary lesions.
Medical - Devices · Guangzhou, GD
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Next Earnings Date
N/A
EPS Estimate
N/A
Revenue Est.
N/A
Last Quarter Results
EPS
N/A
vs Estimate
$0.04
Revenue
$9.90M
vs Estimate
$12.00M
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1BDMD | $31.23M | $0.74 | -0.39% | -63.41% | N/A | N/A | N/A |
| 2BYSI | $31.39M | $0.76 | -2.89% | -54.91% | -44.30% | N/A | vs BDMD |
| 3MDXH | $30.89M | $0.60 | +0.74% | -87.47% | N/A | N/A | vs BDMD |
| 4MIRA | $31.73M | $0.76 | +2.65% | -45.36% | N/A | N/A | vs BDMD |
| 5EUDA | $31.94M | $17.11 | -3.36% | -61.04% | N/A | N/A | vs BDMD |
| 6CRVO | $30.09M | $3.25 | -1.81% | -61.36% | -38.25% | -53.96% | vs BDMD |
forward FY estimate
9.25
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
Consensus Rating
Based on 1 analyst
Average Price Target
$4.00
+440.5% upside
Low
$4.00
Current
$0.74
High
$4.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Dec 2026 | $0.08 | $0.08 | $0.08 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $0.08 | $0.08 | $0.08 | 1 |
| FY 2027 | $0.14 | $0.14 | $0.14 | 1 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Dec 2026 | $17.60M | $17.60M | $17.60M | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $27.52M | $27.52M | $27.52M | 1 |
| FY 2027 | $32.54M | $32.54M | $32.54M | 1 |
Source: FMP Analyst Consensus Estimates. Forward P/E uses the consensus EPS estimate for the fiscal year ending Dec 31, 2026, matching Key Metrics.
